Baseline risk characterization of early versus later adopters of long‐acting paliperidone palmitate formulations. Issue 3 (1st June 2022)

• Record Type: Journal Article
• Authors: Fife, Daniel; Fortin, Stephen; Qiu, Hong; Yamazaki, Michiyo; Najarian, Dean; Voss, Erica A
• Is Part Of: Neuropsychopharmacology reports. Volume 42:Issue 3(2022)
• Page Start: 347
• Page End: 351
• Publication Date: 2022-06-01
• Subjects: baseline characteristics -- differences -- early adopters -- long‐acting paliperidone; Neuropsychopharmacology -- Periodicals; 615.78
• DOI: 10.1002/npr2.12260
• Languages: English
• ISSNs: 2574-173X

Abstract

Abstract: Early Post‐Marketing Phase Vigilance (EPPV) is a unique system that encourages reporting of serious adverse reactions for medications newly introduced to Japan. When a once‐monthly paliperidone palmitate formulation (PP1M) was introduced in Japan in 2013, EPPV detected a signal of increased mortality, but this signal was not subsequently confirmed. To clarify whether that signal reflected increased adverse event reporting or an atypically high baseline mortality risk among early adopters of PP1M, we evaluated the baseline risk characteristics of early, mid, and later adopters of PP1M in a Japanese database and did a similar evaluation of PP1M and the three‐monthly formulation (PP3M) in two US databases. In Japan, early adopters compared with later adopters were older (mean 39.16 vs 33.70 years) but had a lower proportion of male patients (32.0% vs 44.44%), and a lower mean number of antipsychotic medications (distinct active medical substances) other than paliperidone (2.62 vs 2.85). In the United States, the baseline characteristics of early adopters of PP1M and PP3M did not suggest higher mortality risk than later adopters. These results offer no convincing evidence that the unconfirmed early signal of increased mortality with PP1M was due to increased baseline mortality risk among early adopters.